The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 563-568

  Baral, Stefan D ^a,b   Strömdahl, Susanne ^a,b   Beyrer, Chris ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HIV; injecting drug user; preexposure prophylaxis; prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; METHADONE; NALOXONE; OPIATE;

ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG EXCRETION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MALE HOMOSEXUAL; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT COMPLIANCE; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; URINARY EXCRETION; VIRUS TRANSMISSION;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84868370317     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328358e49e     Document Type: Review

References (77)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-434.
4. Martin M, Vanichseni S, Suntharasamai P, et al. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One 2011; 6:e25127.
5. Cohen MS, Baden LR. Preexposure prophylaxis for HIV: where do we go from here? N Engl J Med 2012; 367:459-461.
6. Havlir D, Beyrer C. The beginning of the end of AIDS? N Engl J Med 2012; [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/22809362.
7. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, et al. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet 2010; 376:551-563.
8. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010; 376:355-366.
9. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
10. Beyrer C, Baral S, Kerrigan D, et al. Expanding the space: inclusion of most-atrisk populations in HIV prevention, treatment, and care services. J Acquir Immune Defic Syndr 2011; 57 (Suppl 2):S96-S99.
11. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Strathdee SA. 12 myths about HIV/AIDS and people who use drugs. Lancet 2010; 376:208-211.
12. Shahbazi M, Farnia M, Keramati M. The first evaluation of needle and syringe exchange program in Iranian prisons. Rev Esp Sanidad Penitenciaria 2009; 11:63.
13. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 2006; 41:777-813.
14. Degenhardt L, Mathers B, Vickerman P, et al. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010; 376:285-301.
15. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and country level coverage. Lancet 2010; 375:1014-1028.
16. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One 2010; 5:e8829.
17. Baral S, Sifakis F, Peryskina A, et al. Risks for HIV infection among gay, bisexual, and other men who have sex with men in moscow and St. Petersburg, Russia. AIDS Res Hum Retroviruses 2012; 28:874-879.
18. Ferreira AD, Caiaffa WT, Bastos FI, Mingoti SA. Profile of male Brazilian injecting drug users who have sex with men. CadSaude Publica 2006; 22:849-860.
19. Beyrer C, Wirtz A, Walker D, et al. The global HIV epidemics among men who have sex with men: epidemiology, prevention, access to care and human rights. World Bank. Washington, DC: World Bank Publications; 2011, pp. 156-193.
20. Beyrer C, Baral SD, van Griensven F, et al. Global epidemiology of HIV infection in men who have sex with men. Lancet 2012; 380:367- 377.
21. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010.
22. Baral S, Poteat T, Wirtz A, et al. Global burden of HIV infection among Transgender persons: a systematic review and meta-analysis (THPDC0202). International AIDS Society. XIX International AIDS Conference; Washington, DC 2012; http://pag.aids2012.org/Abstracts.aspx?SID283&AID19729.
23. Baral S, Beyrer C, Muessig K, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and metaanalysis. Lancet Infect Dis 2012; 12:538-549.
24. Gilbert L, El-Bassel N, Terlikbayeva A, et al. Couple-based HIV prevention for injecting drug users in Kazakhstan: a pilot intervention study. J Prev Intervent Community 2010; 38:162-176.
25. Epperson MW, El-Bassel N, Chang M, Gilbert L. Examining the temporal relationship between criminal justice involvement and sexual risk behaviors among drug-involved men. J Urban Health 2010; 87:324-336.
26. Wu E, El-Bassel N, McVinney LD, et al. Feasibility and promise of a couplebased HIV/STI preventive intervention for methamphetamine-using, black men who have sex with men. AIDS Behav 2011; 15:1745-1754.
27. El-Bassel N, Gilbert L, Wu E, et al. Couple-based HIV prevention for lowincome drug users from New York City: a randomized controlled trial to reduce dual risks. J Acquir Immune Defic Syndr 2011; 58:198-206.
28. Epperson MW, Khan MR, El-Bassel N, et al. A longitudinal study of incarceration and HIV risk among methadone maintained men and their primary female partners. AIDS Behav 2011; 15:347-355.
29. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
30. Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention trials network 052 trial. J Infect Dis 2011; 204:1918-1926.
31. Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people who use injection drugs: Implications for 'treatment as prevention'. Curr Opin HIV AIDS 2012; 7:332-338.
32. Wood E, Milloy MJ, Montaner JSG. HIV treatment as prevention among injection drug users. Curr Opin HIV AIDS 2012; 7:151-156.
33. Vlahov D, Celentano DD, Bastos FI, et al. Access to highly active antiretroviral therapy for injection drug users: Adherence, resistance, and death. Cad Saude Publica 2006; 22:705-731.
34. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14:731-747.
35. Sanchez GV, Llibre JM, Torrens M, et al. Effectiveness of antiretroviral therapy in HIV-1-infected active drug users attended in a drug abuse outpatient treatment facility providing a multidisciplinary care strategy. Curr HIV Res 2012; 10:356-363.
36. Werb D, Mills EJ, Montaner JS, Wood E. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a metaanalysis. Lancet Infect Dis 2010; 10:464-469.
37. Brust JC, Litwin AH, Berg KM, et al. Directly observed antiretroviral therapy in substance abusers receiving methadone maintenance therapy does not cause increased drug resistance. AIDS Res Hum Retroviruses 2011; 27:535-541.
38. Cunningham CO, Sohler NL, Cooperman NA, et al. Strategies to improve access to and utilization of healthcare services and adherence to antiretroviral therapy among HIV-infected drug users. Subst Use Misuse 2011; 46:218- 232.
39. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009(3):CD002209. [Epub ahead of print].
40. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroindependent individuals. Cochrane Database Syst Rev. 2011(12):CD003410. [Epub ahead of print].
41. Cooperman NA, Heo M, Berg KM, et al. Impact of adherence counseling dose on antiretroviral adherence and HIV viral load among HIV-infected methadone maintained drug users. AIDS Care 2012; 24:828-835.
42. Berg KM, Litwin A, Li X, et al. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend 2011; 113:192- 199.
43. Nahvi S, Litwin AH, Heo M, et al. Directly observed antiretroviral therapy eliminates adverse effects of active drug use on adherence. Drug Alcohol Depend 2012; 120:174-180.
44. Berg KM, Litwin AH, Li X, et al. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention. Clin Infect Dis 2011; 53:936-943.
45. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376:268- 284.
46. Thompson MA, Mugavero MJ, Rivet Amico K, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel. Ann Intern Med 2012; 156:817-833.
47. Milloy MJ, Kerr T, Buxton J, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:393-399.
48. Palepu A, Milloy MJ, Kerr T, et al. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health 2011; 88:545-555.
49. Jurgens R, Csete J, Amon JJ, et al. People who use drugs, HIV, and human rights. Lancet 2010; 376:475-485.
50. Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203:1215-1221.
51. Milloy MJ, Marshall BD, Kerr T, et al. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS 2012; 26:1049-1063.
52. Suntharasamai P, Martin M, Vanichseni S, et al. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 2009; 104:235-242.
53. Hedrich D, Alves P, Farrell M, et al. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction 2012; 107:501- 517.
54. Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIVinfected opioid dependent released prisoners. PLoS One 2012; 7:e38335.
55. Saber-Tehrani AS, Springer SA, Qiu J, et al. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community - a potential conduit to improved HIV treatment outcomes. Contemp Clin Trials 2012; 33:436-444.
56. Strathdee SA, Shoptaw S, Dyer TP, et al. Towards combination HIV prevention for injection drug users: Addressing addictophobia, apathy and inattention. Curr Opin HIV AIDS 2012; 7:320-325.
57. Kermode M, Armstrong G, Waribam S. Long-term follow up of clients from a community-based opioid substitution therapy programme in Manipur. Indian J Med Res 2011; 134:732-734.
58. Armstrong G, Humtsoe C, Kermode M. HIV risk behaviours among injecting drug users in Northeast India following scale-up of a targeted HIV prevention programme. BMC Public Health 2011; 11 (Suppl 6):S9.
59. Uuskula A, Des Jarlais DC, Kals M, et al. Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia. BMC Public Health 2011; 11:517.
60. Uuskula A, Abel-Ollo K, Markina A, et al. Condom use and partnership intimacy among drug injectors and their sexual partners in Estonia. Sex Transm Infect 2012; 88:58-62.
61. Martin M, Vanichseni S, Suntharasamai P, et al. Drug use and the risk of HIV infection amongst injection drug users participating in an HIV vaccine trial in Bangkok, 1999-2003. Int J Drug Policy 2010; 21:296-301.
62. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
63. Greenberg AE, Tappero J, Choopanya K, et al. CDC International HIV Prevention Research activities among injection drug users in Thailand and Russia. J Urban Health 2005; 82 (3 Suppl 4):iv24-iv33.
64. Migasena S, Suntharasamai P, Pitisuttithum P, et al. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Human Retrovir 2000; 16:655-663.
65. Vanichseni S, Tappero JW, Pitisuttithum P, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS (London, England) 2004; 18:311- 316.
66. Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 2007; 7:667- 674.
67. Human Rights Watch. Torture in the name of treatment: human rights abuses in Vietnam, China, Cambodia, and Lao PDR. New York City, NY: 2012 1- 56432-919-4. http://www.hrw.org/sites/default/files/reports/HHR%20Drug %20Detention%20Brochure-LOWRES.pdf.
68. Di Biagio A, Rosso R, Vitale F, et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: an European case control study. Clin Nephrol 2011; 75:518-523.
69. Rook EJ, Huitema AD, van den Brink W, et al. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 2006; 1:109-118.
70. Interim guidance for PrEP in MSM. CDC: do not expand to other risk groups yet. AIDS alert 2011; 26:44-45.
71. Centers for Disease C, Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011; 60:65-68.
72. HIV/AIDS Programme. Guidance on preexposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva: United Nations, 2012 WC 503.6.
73. Bekker LG, Rebe K, Scheibe A, The Consensus Committee SAHCS. Southern African guidelines for the safe use of preexposure prophylaxis in men who have sex with men who are at risk for HIV infection. S Afr J HIV Med 2012; 13:40-55.
74. International NACPPMoHPFH. Survey of high risk groups in Lahore and Karachi,2005. Islamabad:2006.FHI,Department for InternationalDevelopment National AIDS Control Program Pakistan; Ministry of Health Pakistan; Family Health International http://gametlibrary.worldbank.org/FILES/681-National %20STI%20survey%20Pakistan%202004.pdf
75. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
76. Mayhew S, Collumbien M, Qureshi A, et al. Protecting the unprotected: mixedmethod research on drug use, sex work and rights in Pakistan's fight against HIV/AIDS. Sex Transm Infect 2009; 85 (Suppl 2):ii31-ii36.
77. Singh S, AmbrosioM, Semini I, et al. Revitalizing the HIV response in Pakistan: A systematic review and policy implications. Washington, DC: The World Bank, 2012.